Treatment of the antiphospholipid syndrome

Current Opinion in Rheumatology

Volumn 14, Issue 3, 2002, Pages 238-242

  Roubey, Robert A S ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ANTICOAGULANT AGENT; ANTIOXIDANT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; ESTROGEN; FIBRINOLYTIC AGENT; HEPARIN; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; LOW MOLECULAR WEIGHT HEPARIN; ORAL CONTRACEPTIVE AGENT; PREDNISONE; PROBUCOL; SELECTIVE ESTROGEN RECEPTOR MODULATOR; WARFARIN;

ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; BLEEDING; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DRUG CONTRAINDICATION; DRUG EFFICACY; FERTILIZATION IN VITRO; HUMAN; HYPERCOAGULABILITY; INFARCTION; NEUROLOGIC DISEASE; PREGNANCY DISORDER; PRIORITY JOURNAL; REVIEW; SKIN ULCER; THROMBOSIS;

ABORTION, SPONTANEOUS; ANTIPHOSPHOLIPID SYNDROME; ASPIRIN; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; NERVOUS SYSTEM DISEASES; PREGNANCY; THROMBOSIS;

EID: 0036231528     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200205000-00007     Document Type: Review

References (39)

1. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome
2. Guidelines on the investigation and management of the antiphospholipid syndrome
3. Identification of an Fc gamma receptor-independent mechanism by which intravenous immunoglobulin ameliorates antiphospholipid antibody-induced thrombogenic phenotype
4. Laboratory control of oral anticoagulant treatment by the INR system in patients with the antiphospholipid syndrome and lupus anticoagulant: Results of a collaborative study involving nine commercial thromboplastins
5. Monitoring therapy with vitamin K antagonists in patients with lupus anticoagulant: Effect on different tests for INR determination
6. Technetium-99m-ECD SPECT in antiphospholipid antibody syndrome: A drastic improvement in brain perfusion by antiplatelet therapy
7. Frequency, potential risk and therapeutic intervention in end-stage renal disease patients with antiphospholipid antibody syndrome: A multicenter study
8. Characteristics of patients with antiphospholipid syndrome with major bleeding after oral anticoagulant treatment
9. Effect of thrombophylaxis on uterine and fetal circulation in pregnant women with a history of pregnancy complications
10. Recurrent pregnancy loss with antiphospholipid antibody: A systematic review of therapeutic trials
11. A study of 75 pregnancies in patients with antiphospholipid syndrome
12. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin
13. Risk factors associated with fetal losses in treated antiphospholipid syndrome pregnancies: A multivariate analysis
14. Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? A randomized controlled trial
15. Aspirin to treat obstetric manifestations of the antiphospholipid syndrome
16. A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy
17. Pregnancy outcome in recurrent spontaneous abortion associated with antiphospholipid antibodies: A comparative study of intravenous immunoglobulin versus prednisone plus low-dose aspirin
18. Recurrent pregnancy loss: Summary and clinical recommendations
19. Update on the management of the pregnant patient with antiphospholipid antibody
20. Management of pregnancy in antiphospholipid syndrome
21. How to treat women with antiphospholipid antibodies in pregnancy?
22. Pregnancy outcome is not affected by antiphospholipid antibody status in women referred for in vitro fertilization
23. High thrombosis rate after fetal loss in antiphospholipid syndrome: Effective prophylaxis with aspirin
24. Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies: Do the benefits outweigh the risks? A decision analysis
25. Catastrophic antiphospholipid syndrome: Clues to the pathogenesis from a series of 80 patients
26. Can neurologic manifestations of Hughes (antiphospholipid) syndrome be distinguished from multiple sclerosis? Analysis of 27 patients and review of the literature
27. Warfarin for multiple sclerosis?
28. Acute optic neuropathy and transverse myelopathy in patients with antiphospholipid antibody syndrome: Favorable outcome after treatment with anticoagulants and glucocorticoids
29. Migraine in Hughes syndrome: Heparin as a therapeutic trial?
30. Chorea and antiphospholipid antibodies: Treatment with methotrexate
31. Successful treatment of rheumatic chorea with carbamazepine
32. Stasis ulcers refractory to therapy: Accelerated healing by treatment with clopidogrel ± dalteparin: A preliminary report
33. Recombinant tissue plasminogen activator for the treatment of cutaneous infarctions in antiphospholipid antibody syndrome: A case report
34. Autologous skin transplantation for widespread cutaneous necrosis in secondary antiphospholipid syndrome
35. Exogenous estrogen in systemic lupus erythematosus: Oral contraceptives and hormone replacement therapy
36. Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase 2 inhibitors: A report of four cases
37. Hopkins Lupus Cohort: 1999 Update
38. Antioxidant susceptibility of pathogenic pathways in subjects with antiphospholipid antibodies: A pilot study
39. Synthesis of LJP 993, a multivalent conjugate of the N-terminal domain of β2GPI and suppression of an anti-β2GPI immune response